ロード中...
Biosimilars: How Can Payers Get Long-Term Savings?
The term ‘biosimilar’ refers to an alternative similar version of an off-patent innovative originator biotechnology product (the ‘reference product’). Several biosimilars have been approved in Europe, and a number of top-selling biological medicines have lost, or will lose, patent protection over th...
保存先:
| 出版年: | Pharmacoeconomics |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863918/ https://ncbi.nlm.nih.gov/pubmed/26792791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0380-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|